Presented by: Dr Raktima Kerni

INNOVATION ON DEMAND: Exploring how contract research organizations help small biotech firms grow – A Qualitative Study

Guided by: Dr Deepti Sharma

Introduction & Background

- The biotech industry is a major driver of healthcare innovation, especially in drug and vaccine discovery.
- Small biotech firms are key sources of innovation but face significant challenges: limited resources, expertise, and regulatory hurdles.
- Contract Research Organizations (CROs) provide essential R&D support, regulatory expertise, and access to infrastructure, enabling small firms to innovate and grow.

Research Objectives

Main Aim:
To explore the strategic role of CROs in supporting the growth and innovation of small biotech firms, with a focus on drug and vaccine discovery.



Specific Objectives:

1. Identify key services provided by CROs in drug and vaccine development.
2. Analyze how CRO partnerships impact research efficiency, regulatory compliance, and time-to-market for small biotech firms.
3. Examine challenges and best practices in CRO–biotech collaborations.
4. Provide recommendations for enhancing the effectiveness of CRO support for biotech startups.

Methodology

Qualitative research design

- 6 case studies of CRO–biotech partnerships
- 2 expert interviews
- 2 document analyses (Memoranda of Understanding)

Thematic analysis and ***triangulation*** used to ensure reliability and depth of findings.





Evolution of CROs

1970- 1980s

Emergence of early CROs offering basic clinical services as a cost-saving strategy

1990s

Regulatory tightening (ICH-GCP) increased demand for compliant external partners

2000s

Global expansion of CRO services, enabling access to international patient populations

2010s

Rise of full-service CROs, integrating preclinical, clinical, and regulatory services.

2020s

Strategic alliances with biotech and AI integration for personalized medicine and data-driven trials

The global CRO market reached an estimated USD 80.1 billion in 2023 and is projected to exceed USD 100 billion by 2026.

CRO Market Growth

Market Value:
2024: USD 65.06 billion

2034: Projected USD 126.17 billion

Key Drivers:

Increased outsourcing by pharma and biotech companies

Demand for faster R&D and cost reduction



Global & Regional Market Trends

Small biotech firms face challenges like limited resources and high R&D costs. CROs offer outsourced research and development services to overcome these hurdles.



Reasons:

Large and diverse patient pools

Lower clinical trial costs

Expanding pharma and biotech sectors

Asia-Pacific (especially India, China) is the fastest-growing region.

Core Services Provided by CROs

- Preclinical research (in vitro assays, animal studies)
- Clinical trial management (design, monitoring, global execution)
- Regulatory consulting (dossier preparation, regulatory interactions)
- Biobanking and biorepository services
- Genomic and data analysis

STUDY SETTING AND POPULATION

•Study setting:
The study will be conducted in collaboration with BioHubb, including biotech firms and CROs globally, with a focus on north America, Europe, and India. Interviews may be conducted online due to geographical diversity.

•Sampling size:
Purposive and convenience sampling will be used for approximately 10 participants, including 6 biotech case studies, 2-3 CRO representatives, and 1-2 industry experts. This size is appropriate for qualitative depth

•Inclusion criteria:
Small biotech companies (<250 employees) in drug/vaccine R&D, CROs offering services like biobanking and regulatory consulting, and key stakeholders (founders, R&D leads, project managers, industry analysts).

•Exclusion criteria:
•CROs working solely with large pharmaceutical companies, biotech firms without CRO collaboration history, and respondents lacking decision-making or project experience in collaborations.

Data Collection: Case Studies

Catalyst Clinical Research:
Enhanced trial oversight through digital integration (Medidata Rave CTMS), providing real-time visibility and regulatory compliance.

Syneos Health:
Leveraged predictive analytics (Medidata Detect) for real-time risk-based monitoring, improving data quality and trial transparency.

Mid-Sized CRO & Pharma Sponsor:
Rapidly implemented eTMF system (Rave eTMF) in eight weeks, enhancing audit-readiness and streamlining document workflows.

Global CRO:
Accelerated imaging trial operations using Rave Imaging, resulting in 86% faster setup and 66% reduction in preparation time.

PHASTAR:
Ensured data continuity through rapid migration during live trials (13 days), safeguarding study integrity and timelines.

Thematic Framework: Key Insights

Leveraging Technology

CROs drive operational transformation through intelligent oversight and digital integration, using real-time data for proactive decision-making.

Infrastructure Enablers

CROs provide speed and efficiency in trial setup, offering plug-and-play solutions for biotechs without in-house systems.

Strategic Partnership

Deep collaboration over transactional service, fostering shared accountability, alignment on values, agility, and vision.

Regulatory Compliance

CROs build inspection-ready systems without internal burden and bridge regulatory complexity during live trials.

Specialized Expertise

Empowering scientific progress through functional specialization in biometrics, imaging, and biostatistics, co-creating trial designs.

Key Informant Interviews & Insights: Strategic Value of CROs

Retro Biotech (Preclinical Diagnostics)

Co-founder shared insights on CRO selection, challenges (timeline mismatches), and impact (30% faster regulatory prep, boosted investor confidence).

•Engaged CROs for trial management and regulatory planning.
•Achieved 30% faster regulatory readiness and increased investor confidence.
•Challenges included timeline mismatches and niche assay unfamiliarity.

BioHubb (Hybrid CRO-Biobank)

Co-founder discussed dual CRO/biobank model, client focus (60% small/mid-sized biotechs), and co-creation partnerships.

•Supports ~60% small biotech startups with IRB facilitation, biospecimens, and regulatory consulting.
•Enabled an AI-based diagnostics firm to reach clinical proof-of-concept in 6 months.
•Operates on shared-risk, joint-IP partnerships, acting as a co-innovator.

Interviews revealed that CROs are seen as strategic partners, not just vendors. They accelerate regulatory processes and proof-of-concept, despite challenges like ethics delays and funding gaps.

Document Analysis

Two documents analysed between small biotech firms and CROs

Memoranda of Understanding (MoU)

- Revealed ethical, operational partnerships for plasma R&D emphasizing governance, standardization, and financial balance.

iProcess Document

- Outlined cryopreserved oncology sample logistics, highlighting scientific viability, ethical contextualization, and co-ownership models.

Findings:

- Clearly defined roles and responsibilities foster smoother collaboration.
- Emphasis on data security and regulatory compliance.
- Performance-based milestones encourage timely project delivery.

Key Aspects Examined:

- Service agreements and confidentiality clauses
- Regulatory and quality compliance requirements
- Intellectual property (IP) arrangements
- Milestones, timelines, and performance metrics

These triangulated methods provide a robust understanding of CROs' role in de-risking, accelerating, and strategically enabling small biotech firms in dynamic, resource-constrained environments.

Triangulating Key Findings

Our methodology integrated case studies, interviews, and document analysis, demonstrating strong convergence across data sources. Core themes like strategic co-development, regulatory facilitation, and biobank integration were consistently highlighted.

Case Studies

Provided in-depth contextual understanding of CRO-biotech interactions.



Document Analysis

Offered insights into formal agreements and public strategies.

Interview

Revealed nuanced perspectives and ecosystem-level policy gaps.

Key Themes in Biotech Innovation

Our study reveals that CROs are increasingly strategic partners in biotech innovation, offering multifaceted support to resource-constrained small firms. Five key themes emerged, highlighting their evolving role beyond traditional vendor services.

1. Strategic Partnerships

CROs are transitioning from vendors to co-development partners.

2. Regulatory Navigation

CROs accelerate regulatory approvals and compliance readiness.

3. Infrastructure & Agility

CROs provide scalable, technology-enabled solutions for efficiency.

4. Biobanking Integration

Innovative biobank access models support diagnostics startups.

5. Coordination Gaps

Issues like regulatory delays and budget mismatches persist.

Challenges and Opportunities for CROs

Regulatory Delays

Ethics bottlenecks present an opportunity for CROs to develop digital IRB platforms for streamlined approvals.

Assay Specialization

A lack of diagnostic expertise in some CROs creates a need for specialized diagnostic teams.

Financial Access

Budget mismatches can be addressed by CROs offering modular pricing models to small biotechs.

Biobank Gaps

Poor infrastructure in biobanks offers an opportunity for CROs to lead in integrated biobank solutions.

Addressing these challenges will allow CROs to further solidify their role as integrated innovation partners, leading to more efficient and successful biotech development.

CROs: From Vendors to Strategic Allies

Previous literature often viewed CROs as mere operational vendors. However, this study affirms their evolving role as strategic partners, with evidence of shared-risk models and co-developed intellectual property. Their regulatory expertise is a key differentiator, crucial for navigating the complex landscape of drug and diagnostic development.

Evolving Role

CROs are now strategic partners, not just vendors, engaging in shared-risk models and co-developed IP.

Regulatory Expertise

Embedding regulatory specialists ensures continuity and timely approvals across regions like FDA and EMA.

Specialized Knowledge

CROs with domain-specific expertise bridge gaps in niche therapeutic areas, offering assay standardization and genomic data analysis.

Study Strengths and Limitations

The study's reliability was enhanced by its triangulated methodology and diverse case pool, offering a 360-degree understanding from both CRO and biotech perspectives. However, limitations include a small sample size, restricted document depth, and a primary focus on India.

Strengths

- Triangulated Methodology
- Diverse Case Pool
- Dual-Perspective Insight



Limitations

- Limited Sample Size
- Restricted Document Depth
- Geographic Concentration

Policy and Practice Recommendations

To foster biotech innovation, policymakers should streamline IRB approvals, offer innovation incentives for CRO-startup partnerships, and establish integrated biobanking infrastructure. CROs must evolve into innovation enablers by offering modular services and co-ownership models.



Conclusion and Future Outlook

CROs are critical co-drivers of innovation for emerging biotech firms, providing essential support across regulatory, operational, and scientific domains. Strengthening this collaboration through policy, infrastructure, and a shared vision is vital for a resilient healthcare ecosystem.



For Biotech Startups	Align strategically with CROs based on expertise and long-term potential, not just cost.
For CROs	Continue evolving business models to offer customizable portfolios and data analytics integration.
For Policymakers	Implement regulatory reforms and incentives to strengthen CRO–biotech collaborations.
For Investors	Guide startups towards effective CRO partnerships, encouraging due diligence and milestone-based outsourcing.

References

1. IQVIA Institute. (2023). Biopharma innovation and development: Outsourcing trends. Available from: https://www.iqvia.com
2. Contract Research Organization (CRO) Market Size, Share, and Trends 2025 to 2034 (2024). Available from: https://www.precedenceresearch.com/contract-research-organization-market
3. Thermo Fisher Scientific. PPD DCT Network Launch. 2022. https://www.businesswire.com/news/home/20221005005447/en/Thermo-Fisher-Scientific-Introduces-Decentralized-Clinical-Trials-Network
4. Unlocking Growth in Contract Research Organization (CRO) Market 2025-2033 (2024). Available from: https://www.datainsightsmarket.com/reports/contract-research-organization-cro-1466299#
5. Biotech companies to increase R&D spend but highlight complexity of clinical trials – ICON (2024). Available from: https://investor.iconplc.com/news-releases/news-release-details/biotech-companies-increase-rd-spend-highlight-complexity
6. MarketsandMarkets. Contract Research Organization Services Market / CRO Services Market by Type (Early Phase, Clinical, Lab, Consulting, Data Management), Therapeutic Area (Cancer, Infectious Disease, Neurology, Dermatology, Immunology, Haematology, Vaccines, CGT) - Global Forecast to 2029. 2022 Jun 13. Available from: https://www.marketsandmarkets.com/Market-Reports/contract-research-organization-service-market
7. McKinsey & Company. (2023). Biotech in the Fast Lane: Transforming R&D through Strategic Partnerships. Available from: https://www.mckinsey.com/industries/life-sciences/our-insights/cros-and-biotech-companies-fine-tuning-the-partnership
8. Grant Thornton. Pharma, Healthcare, and Biotech Sector M&A and PE Investments Report. 2024. Available from: https://www.grantthornton.in/globalassets/1.-member-firms/india/assets/pdfs/dealtracker/q2_2024_dealtracker.pdf
9. Reuters. India's Mankind Pharma to buy Bharat Serums in a $1.6 billion deal. (2024 Jul 25). Available from: https://in.marketscreener.com/quote/stock/MANKIND-PHARMA-LIMITED
10. Business Standard. Carlyle-backed SeQuent, Viyash Life Sciences announce Rs 8,000 crore merger. 2024 Sep 27. Available from: https://www.business-standard.com/companies/news/carlyle-backed-sequent-scientific-and-viy

Presented by: Dr Raktima Kerni

Thank You for your Attention